Published in Am Rev Respir Dis on May 01, 1977
Formulation and evaluation of microemulsion based delivery system for amphotericin B. AAPS PharmSciTech (2008) 0.81
Collaborative investigation of variables in susceptibility testing of yeasts. Antimicrob Agents Chemother (1990) 8.42
Multicenter evaluation of a broth macrodilution antifungal susceptibility test for yeasts. Antimicrob Agents Chemother (1993) 8.36
In vitro studies with 5-fluorocytosine. Appl Microbiol (1969) 8.01
Comparison of relative susceptibilities of Candida species to three antifungal agents as determined by unstandardized methods. Antimicrob Agents Chemother (1987) 7.33
Quality control limits for broth microdilution susceptibility tests of ten antifungal agents. J Clin Microbiol (2000) 6.33
Comparison study of broth macrodilution and microdilution antifungal susceptibility tests. J Clin Microbiol (1991) 6.17
Quality control guidelines for National Committee for Clinical Laboratory Standards recommended broth macrodilution testing of amphotericin B, fluconazole, and flucytosine. J Clin Microbiol (1995) 6.02
Results of a survey of antifungal susceptibility tests in the United States and interlaboratory comparison of broth dilution testing of flucytosine and amphotericin B. J Clin Microbiol (1986) 5.19
Optimizing the correlation between results of testing in vitro and therapeutic outcome in vivo for fluconazole by testing critical isolates in a murine model of invasive candidiasis. Antimicrob Agents Chemother (1998) 4.95
Antifungal susceptibility testing: practical aspects and current challenges. Clin Microbiol Rev (2001) 4.49
Selection of candidate quality control isolates and tentative quality control ranges for in vitro susceptibility testing of yeast isolates by National Committee for Clinical Laboratory Standards proposed standard methods. J Clin Microbiol (1994) 3.62
Multisite reproducibility of colorimetric broth microdilution method for antifungal susceptibility testing of yeast isolates. J Clin Microbiol (1994) 3.46
Standardized susceptibility testing of fluconazole: an international collaborative study. Antimicrob Agents Chemother (1992) 3.19
Evaluation of possible correlations between antifungal susceptibilities of filamentous fungi in vitro and antifungal treatment outcomes in animal infection models. Antimicrob Agents Chemother (1998) 3.00
Correlation of MIC with outcome for Candida species tested against voriconazole: analysis and proposal for interpretive breakpoints. J Clin Microbiol (2006) 2.86
Wild-type MIC distributions, epidemiological cutoff values and species-specific clinical breakpoints for fluconazole and Candida: time for harmonization of CLSI and EUCAST broth microdilution methods. Drug Resist Updat (2010) 2.59
In vitro activity of 5-fluorocytosine against Candida and Torulopsis species. Antimicrob Agents Chemother (1973) 2.54
Comparison of the in vitro antifungal activities of miconazole and a new imidazole, R41,400. J Infect Dis (1978) 2.51
In vitro antifungal activity of clotrimazole (Bay b 5097). Infect Immun (1971) 2.48
Bioassay for hamycin and amphotericin B in serum and other biological fluids. Appl Microbiol (1969) 2.23
Treatment of cryptococcal meningitis with combination amphotericin B and flucytosine for four as compared with six weeks. N Engl J Med (1987) 2.20
Treatment of systemic mycoses with ketoconazole: emphasis on toxicity and clinical response in 52 patients. National Institute of Allergy and Infectious Diseases collaborative antifungal study. Ann Intern Med (1983) 2.17
In vitro studies with combinations of 5-fluorocytosine and amphotericin B. Antimicrob Agents Chemother (1975) 2.10
Wild-type MIC distribution and epidemiological cutoff values for Aspergillus fumigatus and three triazoles as determined by the Clinical and Laboratory Standards Institute broth microdilution methods. J Clin Microbiol (2009) 1.99
Therapy of cryptococcosis with a combination of flucytosine and amphotericin B. J Infect Dis (1975) 1.88
Multicenter comparison of a colorimetric microdilution broth method with the reference macrodilution method for in vitro susceptibility testing of yeast isolates. Diagn Microbiol Infect Dis (1994) 1.88
New method for susceptibility testing with antifungal agents. Antimicrob Agents Chemother (1975) 1.83
In vitro and in vivo studies with BL-S786, cefoxitin, and cefamandole. Antimicrob Agents Chemother (1978) 1.82
In-vitro studies with SF 86-327, a new orally active allylamine derivative. Sabouraudia (1985) 1.76
Toxicity of amphotericin B plus flucytosine in 194 patients with cryptococcal meningitis. Am J Med (1987) 1.65
In vitro susceptibility of Cryptococcus neoformans to amphotericin B, hamycin, and 5-fluorocytosine. Antimicrob Agents Chemother (Bethesda) (1968) 1.62
In vitro studies with miconazole and miconazole nitrate. J Antimicrob Chemother (1977) 1.61
In vitro activities of five oral cephalosporins against aerobic pathogenic bacteria. Antimicrob Agents Chemother (1977) 1.60
In vitro studies with cefazolin. Antimicrob Agents Chemother (1974) 1.55
In vitro and in vivo evaluation of antifungal agents. Eur J Clin Microbiol Infect Dis (1989) 1.52
Multicenter evaluation of broth microdilution method for susceptibility testing of Cryptococcus neoformans against fluconazole. J Clin Microbiol (1996) 1.51
Correlation of fluconazole MICs with clinical outcome in cryptococcal infection. Antimicrob Agents Chemother (2000) 1.51
In vitro studies with R 51,211 (itraconazole). Antimicrob Agents Chemother (1984) 1.48
Antifungal activity of 5-fluorocytosine as measured by disk diffusion susceptibility testing. J Infect Dis (1977) 1.47
Multisite reproducibility of MIC results by the Sensititre YeastOne colorimetric antifungal susceptibility panel. Diagn Microbiol Infect Dis (1998) 1.46
Pharmacokinetics and tolerance of ciprofloxacin after sequential increasing oral doses. Antimicrob Agents Chemother (1986) 1.46
In vitro susceptibility testing with tobramycin. Antimicrob Agents Chemother (1972) 1.38
New medium for in vitro susceptibility studies with amphotericin B. Antimicrob Agents Chemother (1976) 1.37
Rapid determination of serum 5-fluorocytosine levels by high-performance liquid chromatography. Antimicrob Agents Chemother (1978) 1.36
Infection due to the fungus Acremonium (cephalosporium). Medicine (Baltimore) (1991) 1.35
Dematiaceous fungal pathogens isolated from nature. Mycopathologia (1980) 1.33
The evolution of pulmonary cryptococcosis: clinical implications from a study of 41 patients with and without compromising host factors. Ann Intern Med (1981) 1.31
Wild-type MIC distributions and epidemiological cutoff values for amphotericin B, flucytosine, and itraconazole and Candida spp. as determined by CLSI broth microdilution. J Clin Microbiol (2012) 1.27
Intra- and interlaboratory study of a method for testing the antifungal susceptibilities of dermatophytes. J Clin Microbiol (2004) 1.26
Microdilution antifungal susceptibility testing of Candida albicans and Cryptococcus neoformans with and without agitation: an eight-center collaborative study. Antimicrob Agents Chemother (1996) 1.26
N-formimidoyl thienamycin (MK0787): in vitro study. Antimicrob Agents Chemother (1981) 1.26
Clinical evaluation of the Sensititre YeastOne colorimetric antifungal plate for antifungal susceptibility testing of the new triazoles voriconazole, posaconazole, and ravuconazole. J Clin Microbiol (2004) 1.23
Treatment of systemic mycoses with ketoconazole: in vitro susceptibilities of clinical isolates of systemic and pathogenic fungi to ketoconazole. J Infect Dis (1985) 1.22
5-fluorocytosine in human candidiasis. Antimicrob Agents Chemother (Bethesda) (1970) 1.22
Detection of candida antigenemia by counterimmunoelectrophoresis in patients with invasive candidiasis. J Infect Dis (1979) 1.20
In vitro activities of polyene and imidazole antifungal agents against unusual opportunistic fungal pathogens. Mycoses (1990) 1.20
Serotype B/C Cryptococcus neoformans isolated from patients in nonendemic areas. J Clin Microbiol (1982) 1.19
Urinary tract infections due to Candida albicans. Rev Infect Dis (1983) 1.19
Therapeutic failures with miconazole. Antimicrob Agents Chemother (1978) 1.14
Laboratory evaluation of serological tests for systemic candidiasis: a cooperative study. J Clin Microbiol (1977) 1.10
Light sensitivity of prepared solutions of amphotericin B. Am Rev Respir Dis (1973) 1.09
In vivo studies with ambruticin in murine histoplasmosis. Antimicrob Agents Chemother (1978) 1.09
A comparative study of the disc diffusion method with the broth microdilution and Etest methods for voriconazole susceptibility testing of Aspergillus spp. J Antimicrob Chemother (2004) 1.08
Exoantigen test for differentiation of Exophiala jeanselmei and Wangiella dermatitidis isolates from other dematiaceous fungi. J Clin Microbiol (1984) 1.08
Exoantigen test for Cladosporium bantianum, Fonsecaea pedrosoi, and Phialophora verrucosa. J Clin Microbiol (1986) 1.08
In vitro studies with ambruticin, a new antifungal antibiotic. Antimicrob Agents Chemother (1978) 1.07
In vitro susceptibility studies with netilmicin: comparison of a 10-microgram netilmicin disk with a standardized 10-microgram gentamicin disk. Antimicrob Agents Chemother (1978) 1.06
A comparison of bifonazole (BAY H 4502) with clotrimazole in vitro. Sabouraudia (1982) 1.05
Near-drowning complicated by brain abscess due to Petriellidium boydii. Arch Neurol (1982) 1.05
Sino-orbital aspergillosis treated with combination antifungal therapy. Successful therapy after failure with amphotericin B and surgery. JAMA (1980) 1.05
Evaluations of a patient isolator system. I. Evaluations of subsystems and procedures for sterilization and concurrent sanitation. Arch Environ Health (1965) 1.04
Josamycin and rosamicin: in vitro comparisons with erythromycin and clindamycin. Antimicrob Agents Chemother (1976) 1.01
In-vitro inhibitory activities of 2 new orally absorbable imidazole derivatives: BAY n 7133 and BAY 1 9139. Sabouraudia (1983) 0.99
Clinical and laboratory studies of a new micronized preparation of hamycin in systemic mycoses in man. Antimicrob Agents Chemother (Bethesda) (1967) 0.99
Penetration of amphotericin B into the human eye. J Infect Dis (1983) 0.98
Brain abscess caused by Cladosporium trichoides. Arch Intern Med (1976) 0.97
In vivo studies with Bay b 5097. Antimicrob Agents Chemother (Bethesda) (1970) 0.97
Antifungal susceptibility testing of yeasts: a brief overview. Clin Infect Dis (1993) 0.96
Bioassay for miconazole. Antimicrob Agents Chemother (1977) 0.96
Multicenter study of anidulafungin and micafungin MIC distributions and epidemiological cutoff values for eight Candida species and the CLSI M27-A3 broth microdilution method. Antimicrob Agents Chemother (2013) 0.96
In vitro antibacterial activity of norfloxacin compared with eight other antimicrobial agents. Eur J Clin Microbiol (1983) 0.96
Isolation of cladosporium trichoides from nature. Mycopathologia (1977) 0.95
Diffusion disk susceptibility testing with cefaclor. Antimicrob Agents Chemother (1978) 0.95
In vitro comparison of the antifungal activities of R34,000, miconazole and amphotericin B. Chemotherapy (1978) 0.93